Inteliquet, a leading provider of intelligent technology, advanced insights, and expertise for clinical research, patient treatment and translational medicine, announced findings of a survey aimed at examining adoption of real-world data (RWD) in healthcare and clinical research. The survey included professionals from Pharma, Biopharma, MedTech, and Medical Device companies, as well as Contract Research Organizations (CROs).
Access to Robust Data, Primary Patient Journey Data Still Pose a Challenge
The findings note a concerning trend: Data being rapidly adopted may not be the best data when it comes to providing proper analytics and insight.
Although the industry is rapidly adopting RWD, significant barriers and challenges remain to accessing robust, primary patient data, which affects the use of real-world evidence (RWE), the analysis derived from the data.
“Accumulating data is not the significant problem for Life Sciences; accumulating the right data is,” said Marie E. Lamont, Interim President and Chief Operating Officer at Inteliquet. “There is a need to better organize and validate data to improve its RWE utility in our highly regulated industry. As 2020 begins and organizations devote more resources to RWD, it is important to improve the quality of the data to reflect the reality on the ground rather than compound the current challenges. Even the best technology in the world will fail without proper RWD—data that are specific, relevant, and timely.”
While RWD and RWE have rapidly evolved in recent years, organizations continue to grapple with issues related to data sources and the complexity of applying digital analytics. On average, each organization surveyed struggles with:
- Accessing robust data (cited by 44 percent of respondents).
- Accessing to primary patient journey data (39 percent).
- Gaining internal knowledge/understanding of where RWD/RWE analyses can be applied (37 percent).
Supporting Clinical Trial Designs, Clinical Development Among the Top Current Uses for RWD
An overwhelming majority of respondents, 91 percent, report they currently use RWD in clinical development and decision-making, and 84 percent have internal systems to capture and analyze RWD. On average, organizations polled use RWD in:
- Clinical trial designs (65 percent of respondents).
- Early R&D preclinical planning (52 percent).
- Clinical development (52 percent).
- Post-market observational studies (50 percent).
Organizations Will Devote More Resources to RWD in 2020 and Invest in Genomic Data, Other Sources
Organizations expect to substantially boost the resources they commit to RWD:
- 89 percent of organizations plan to grow their budgets in 2020.
- Two-thirds (66 percent) said they will increase their budgets by 20 percent or more.
- Nearly half (46 percent) said their budgets will increase by more than 40 percent.
- At least 53 percent of responding organizations already allocate more than $100,000 per year to RWD.
Currently, the most common sources of RWD are electronic health records (used by 58 percent of respondents) and population health sources of aggregated data (used by 54 percent of respondents). However, respondents identified three types of data that they would like to use more aggressively in the future:
- 67 percent of respondents said they see value in accessing data from mobile devices, social media, health apps, wearables, or other biometric devices, although only 49 percent currently use this data source.
- 47 percent of respondents are considering using genomic data and markers more aggressively in the future, compared with just 39 percent who are currently using it.
- 54 percent of respondents plan to expand their use of health insurance claims and billing data, compared with 46 percent of organizations currently using this data.